WuXi STA Opens a New Clinical Supply Service Facility at Shanghai Waigaoqiao Site

(2023年)

New service further accelerates drug candidates to clinical trials through CRDMO platform
Shanghai, China, September 30, 2022 - WuXi STA, a WuXi AppTec company, today celebrated the inauguration of a new Clinical Supply Service (CSS) facility at the Shanghai Waigaoqiao site to accelerate drug candidates to clinical trials for its global customers. With the new facility in operation, WuXi STA further expands its CRDMO platform to include API and drug product development, manufacturing, packaging, labeling and distribution from preclinical to commercial phase.

The new CSS facility is designed to accommodate a wide range of storage and packaging conditions and provides complete clinical supply lifecycle management service to support global clinical trials. The CSS service covers primary and secondary packaging design, label design and printing, packaging and labeling, storage and distribution, including cold chain logistics, clinical distribution, as well as clinical trial material (CTM) return and destruction in China.

In addition, WuXi STA's proven quality system in API, drug product, analytical, and CSS allows a seamless transition of CTM from CMC to CSS project management within one quality team to ensure a fast, flexible, and reliable clinical supply solution to support global customers.

As an industry-leading Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA has 12 sites across North America, Europe, and Asia. The opening of the new CSS facility demonstrated WuXi STA's ongoing effort to expand its CRDMO platform to better support its global partners.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, noted: "WuXi STA is committed to enabling our global customers with an integrated CRDMO platform, and we never stop expanding this platform with new capacity and capability. With the inauguration of our new Clinical Supply Service facility in Shanghai, we look forward to supporting our customers accelerate their innovative therapies to market for patients worldwide."